A Randomized, Double-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety and Efficacy of Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)
Latest Information Update: 25 Sep 2023
At a glance
- Drugs DMI 9523 (Primary)
- Indications Adult respiratory distress syndrome; Post acute COVID 19 syndrome
- Focus Adverse reactions
- Acronyms Long COVID
- Sponsors Ampio Pharmaceuticals
- 16 May 2022 Status changed from active, no longer recruiting to completed.
- 29 Mar 2022 According to an Ampio Pharmaceuticals media release, Enrollment was completed in December 2021, and the Day 60 post-treatment safety and efficacy measures are currently underway.
- 29 Mar 2022 According to an Ampio Pharmaceuticals media release, is on track to complete the data analysis by the end of the second quarter of 2022.